Transcranial focused ultrasound phase correction using the hybrid angular spectrum method

The InSightec Exablate system is the standard of care used for transcranial focused ultrasound ablation treatments in the United States. The system calculates phase corrections that account for aberrations caused by the human skull. This work investigates whether skull aberration correction can be improved by comparing the standard of care InSightec ray tracing method with the hybrid angular spectrum (HAS) method and the gold standard hydrophone method. Three degassed ex vivo human skulls were sonicated with a 670 kHz hemispherical phased array transducer (InSightec Exablate 4000). Phase corrections were calculated using four different methods (straight ray tracing, InSightec ray tracing, HAS, and hydrophone) and were used to drive the transducer. 3D raster scans of the beam profiles were acquired using a hydrophone mounted on a 3-axis positioner system. Focal spots were evaluated using six metrics: pressure at the target, peak pressure, intensity at the target, peak intensity, positioning error, and focal spot volume. For three skulls, the InSightec ray tracing method achieved 52 +/- 21% normalized target intensity (normalized to hydrophone), 76 +/- 17% normalized peak intensity, and 0.72 +/- 0.47 mm positioning error. The HAS method achieved 74 +/- 9% normalized target intensity, 81 +/- 9% normalized peak intensity, and 0.35 +/- 0.09 mm positioning error. The InSightec-to-HAS improvement in focal spot targeting provides promise in improving treatment outcomes. These improvements to skull aberration correction are also highly relevant for the applications of focused ultrasound neuromodulation and blood brain barrier opening, which are currently being translated for human use.

Automated summary

The study compared different methods for skull aberration correction and found that the HAS method outperformed the InSightec ray tracing method in target intensity, peak intensity, and positioning error. These results demonstrate the promise of the HAS method in improving treatment outcomes.